The effects of anagrelide on human megakaryocytopoiesis
| Autor: | Robert M. Petitt, Lee A. Forstrom, Murray N. Silverstein, Jerzy S. Tarach, Lawrence A. Solberg, Ayalew Tefferi, Karl J. Oles |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Blood Platelets Male Cell Survival Pharmacology Myeloproliferative Disorders Megakaryocyte medicine Humans Platelet Progenitor cell Cells Cultured Cellular Senescence Megakaryocytopoiesis business.industry Stem Cells Hematology Anagrelide Middle Aged Haematopoiesis medicine.anatomical_structure Immunology Quinazolines Female Glycoprotein IIb/IIIa business Megakaryocytes Cell Division Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | British journal of haematology. 99(1) |
| ISSN: | 0007-1048 |
| Popis: | Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with myeloproliferative disorders. We describe studies aimed at discovering the general mechanism(s) by which anagrelide acts. We examined three hypotheses: (1) anagrelide shortens platelet survival, (2) anagrelide inhibits the proliferation of megakaryocytic-committed progenitor cells (CFU-M), and (3) anagrelide inhibits maturation of megakaryocytes. We observed that anagrelide did not shorten platelet survival. Proliferation of CFU-M in vivo was not affected by anagrelide, although high concentrations of anagrelide inhibited CFU-M in vitro. In-vivo and in-vitro anagrelide altered the maturation of megakaryocytes, causing a decrease in their size and changing other morphometric features. We conclude that anagrelide decreases the number of platelets primarily by interfering with the maturation of megakaryocytes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text